Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells

References

• Druker BJ. STI571 (Gleevec) as a paradigm for cancer therapy. Trends Mol Med 2002;8:14–18.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61: 1441–1446.
   Google Scholar
• Ramadevi N, DPhil B, Kapil B. Mechanisms of resistance to imatinib mesylate in BCR/ABL positive leukemias. Curr Opin Onc 2002;14:616–620.
   Google Scholar
• Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR/ABL tyrosine kinase. Nat Med 2001;7:228–234.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330–1340.
   PubMed Web of Science ®Google Scholar
• Savage DG, Antham KH. Imatinib mesylate: A new oral targeted therapy. N Eng J Med 2002;346:683–693.
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56: 100–104.
   PubMed Web of Science ®Google Scholar
• Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for 5TI571 inhibition of abelson tyrosine kinase. Science 2000289:1938-1942.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias. Lancet Oncol 2003;4:75–85.
   Google Scholar
• Hegedus T, Orifi L, Seprodi A, Varadi A, Sarkadi B, Ken G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochem Biophys Acta 2002;1587:318–325.
   PubMed Web of Science ®Google Scholar
• Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006;57:145–164.
   PubMed Web of Science ®Google Scholar
• Deininger M. Resistance to imatinib: Mechanisms and management. J Natl Compr Canc Netw 2005;3:757–768.
   PubMedGoogle Scholar
• Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931–959.
   PubMed Web of Science ®Google Scholar
• Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42:1007–1017.
   Google Scholar
• Baran Y, Glindaz Y, Ural AU. Cross-resistance to cytosine arabinoside in human acute myeloid leukemia cells selected for resistance to vincristine. Exp Oncol 2006;28:163–165.
   Google Scholar
• Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto C, Birbes H, Hannun YA, Obeid LM. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J Biol Chem 2001;276: 24901–24910.
   PubMed Web of Science ®Google Scholar
• Koybasi S, Senkal CE, Sundararaj K, Spassieva S, Bielawski J, Osta W, Day TA, Jiang JC, Jazwinski SM, Hannun YA, Obeid LM, Ogretmen B. J Biol Chem 2004;279:44311–44319.
   PubMed Web of Science ®Google Scholar
• Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV. Selection and characterization of BCR/ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 2000;96: 1070–1079.
   Google Scholar
• Sultan I, Senkal CE, Ponnusamy S, Bielawski J, Szulc Z, Bielawska A, Hannun YA, Ogretmen B. Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function. Biochem J 2006;393:513–521.
   PubMed Web of Science ®Google Scholar
• Wiesberg E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000;95:3498–3505.
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. Clinical resistance to STI571 cancer therapy caused by BCR/ABL gene mutation or amplification. Science 2003;293: 876–880.
   Web of Science ®Google Scholar
• Reed JC. Regulation of apoptosis by bc1-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 1995;5:541–546.
   Google Scholar
• Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M. Bc1-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996;60: 23–32.
   Google Scholar
• Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A BCR/ABL-independent, Lyn-dependent form of Imatinib mesylate (STI-571) resistance is associated with altered expression of Bc1-2. J Biol Chem 2004;279: 34227–34239.
   PubMed Web of Science ®Google Scholar
• Salomoni P, Condorelli F, Sweeney SM, Calabretta B. Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. Blood 2000;96: 676–684.
   PubMed Web of Science ®Google Scholar
• Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, Prosper F, Fernandez-Luna JL. Blockade of the BCR/ABL kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bc1-xL. J Exp Med 2002;191: 977–984.
   Web of Science ®Google Scholar
• Zamzami N, Brenner C, Marzo I, Susin SA, Kroemer G. Subcellular and submitochondrial mode of action of Bc1-2-like oncoproteins. Oncogene 1998;16: 2265–2282.
   PubMed Web of Science ®Google Scholar
• Amarante-Mendes GP, McGahon AJ, Nishioka WK, Afar DE, Witte ON, Green DR. Bc1-2-independent BCR/ABL-mediated resistance to apoptosis: Protection is correlated with up regulation of Bc1-xL. Oncogene 1998;16: 1383–1390.
   PubMed Web of Science ®Google Scholar